Mologen Ag

Gilead Sciences, Inc.

Mologen Forschungs Entwicklungs Und Vertriebs Gmbh

Matthias Schroff

Manuel Schmidt

Burghardt Wittig

Kerstin Kapp

Alfredo Zurlo

Claas Junghans

Christiane Juhls

Detlef Oswald

Hans Lutz

Bernadette Brzezicha

Christiane Kleuss

Florian Sack

Rasmus Offersen

Janine Loehr

Sven König Merediz

Ole Schmeltz Sogaard

Martin Tolstrup

Janine Löhr

Detlef Oswlad

The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif NNCGNN, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.

Methods of treating a retroviral infection

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.

Combination comprising immunostimulatory oligonucleotides

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.

The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.

Covalently closed non-coding immunomodulatory DNA construct

The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Predictive biomarker for cancer therapy

The invention relates to a multimeric non-coding nucleic acid molecule for modulating the activity of the human or animal immune system, and to a preparation process therefore and a vaccine which comprises the multimeric non-coding nucleic acid molecule.

Multimer for immunostimulation

The invention relates to expression constructs for targeted inhibition of gene expression and methods for their production and which, after transfection thereof into eukaryotic cells, are suitable for inhibiting in a targeted manner these cells formation of defined proteins by RNA interference, wherein the method is a three step method requiring no PCR steps and is carried out in one reaction vessel in a few hours and are suitable for multiple gene expression inhibition.

DNA constructs for specific inhibition of gene expression by RNA interference

Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans and vertebrates.

Substituted, non-coding nucleic acid molecule for therapeutic and prophylactic stimulation of the immune system in humans and higher animals

The invention concerns a vaccine that can induce protection against disease especially in consequence of a lentivirus infection, especially an infection with the Feline Leukosis virus. Such vaccine comprises codon-optimized DNA sequences encoding structural proteins and the most important membrane protein of FeLV.

Vaccine against oncovirus infections such as infections by feline leukosis virus of the cat

Short deoxyribonucleic acid molecules that are partially single-stranded, dumbbell-shaped, and covalently closed, which contain one or more unmethylated cytosine guanosine motif (CpG motif) and exhibit immunomodifying effects. Such molecules can be used for immunostimulation applications in humans or vertebrates.

Covalently closed nucleic acid molecules for immunostimulation

A process to obtain linear double-stranded covalently closed DNA &ldquo;dumbbell&rdquo; constructs from plasmids by restriction digest, subsequent ligation with hairpin oligodesoxyribonucleotides, optionally in the presence of restriction enzyme, and a final digestion with endo- and exonucleolytic enzymes that degrade all contaminating polymeric DNA molecules but the desired construct. The invention also provides a process to obtain said dumbbell constructs employing endonuclease class II enzymes. Furthermore, the invention provides a process to obtain linear, covalently closed DNA molecules, such as plasmids, free from contamination by genomic DNA, by submitting the DNA preparation to a facultative endonucleolytic degradation step and an obligatory exonucleolytic degradation step.

Growing community of inventors

Berlin, Germany

Matthias Schroff